New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 23, 2007, Pages 6505-6510

  Manera, Clementina ^a   Cascio, Maria Grazia ^b   Benetti, Veronica ^a   Allarà, Marco ^b   Tuccinardi, Tiziano ^a   Martinelli, Adriano ^a   Saccomanni, Giuseppe ^a   Vivoli, Elisa ^c   Ghelardini, Carla ^c   Di Marzo, Vincenzo ^b   Ferrarini, Pier Luigi ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

^c Dipartimento di Farmacologia Preclinica e Clinica   (Italy)

Author keywords

1,8 Naphthyridine; Cannabinoid; CB1 receptor; CB2 receptor; Quinoline

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 1,8 NAPHTHYRIDINE DERIVATIVE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; 7 METHOXY 1,8 NAPHTHYRIDINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DEXANABINOL; QUINOLINE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR MODEL; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; HUMANS; MICE; NAPHTHYRIDINES; PAIN MEASUREMENT; QUINOLINES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 35649019741     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.089     Document Type: Article

References (27)

1. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., and Malan Jr. T.P. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3093
2. Iwamura H., Suzuki H., Ueda Y., Kaya T., and Inaba T. J. Pharmacol. Exp. Ther. 296 (2001) 420
3. Ofek O., Karsak M., Leclerc N., Fogel M., Frenkel B., Wright K., Tam J., Attar-Namdar M., Kram V., Shohami E., Mechoulam R., Zimmer A., and Bab I. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 696
4. Sanchez C., de Ceballos M.L., del Pulgar T.G., Rueda D., Corbacho C., Velasco G., Galve-Roperh I., Huffman J.W., Ramon y Cajal S., and Guzman M. Cancer Res. 61 (2001) 5784
5. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., Nagarkatti P.S., and Nagarkatti M. Blood 100 (2002) 627
6. Pertwee R.G. Pharmacol. Ther. 95 (2002) 165
7. Stella N. Glia 48 (2004) 267
8. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., and de Ceballos M.L. J. Neurosci. 25 (2005) 1904
9. Kim K., Moore D.H., Makriyannis A., and Abood M.E. Eur. J. Pharmacol. 542 (2006) 100
10. Valenzano K.J., Tafesse L., Leeb G., Harrison J.E., Boulet J.M., Gottshall S.L., Mark L., Pearson M.S., Miller W., Shan S., Rabadi L., Rotshteyn Y., Chaffer S.M., Turchin P.I., Elsemore D.A., Toth M., Koetzner L., and Whiteside G.T. Neuropharmacology 48 (2005) 658
11. Malan Jr. T.P., Ibrahim M.M., Lai J., Vanderah T.W., Makriyannis A., and Porreca F. Curr. Opin. Pharmacol. 3 (2003) 62
12. Ferrarini P.L., Calderone V., Cavallini T., Manera C., Saccomanni G., Pani L., Ruiu S., and Gessa G.L. Bioorg. Med. Chem. 12 (2004) 1921
13. Manera C., Benetti V., Castelli M.P., Cavallini T., Lazzarotti S., Pibiri F., Saccomanni G., Tuccinardi T., Vannacci A., Martinelli A., and Ferrarini P.L. J. Med. Chem. 49 (2006) 5947
14. Tuccinardi T., Ferrarini P.L., Manera C., Ortore G., Saccomanni G., and Martinelli A. J. Med. Chem. 49 (2006) 984
15. 1H NMR and MS spectra and were found to be in agreement with their structures.
16. Shah K.J., and Coats E.A. J. Med. Chem. 20 (1977) 1001
17. Carboni S., Da Settimo A., Bertini D., Ferrarini P.L., Livi O., Mori Cl., and Tonetti I.o. Gazzetta Chimica Italiana 102 (1972) 253
18. Kaslow C.E., and Clark Wx.R. J. Org. Chem. 18 (1953) 55
19. 50 values (obtained by GraphPad) for the displacement of the bound radioligand by increasing concentrations of the test compounds.
20. Brizzi A., Brizzi V., Cascio M.G., Bisogno T., Sirianni R., and Di Marzo V. J. Med. Chem. 48 (2005) 7343
21. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. J. Comp. Chem. 19 (1998) 1639
22. Song Z.H., Slowey C.A., Hurst D.P., and Reggio P.H. Mol. Pharmacol. 56 (1999) 834
23. O'Callaghan J.P., and Holtzman S.G. J. Pharmacol. Exp. Ther. 192 (1975) 497
24. Male Swiss albino mice (24-26 g) from Morini (San Polo d'Enza, Italy) were used. Ten mice were housed per cage. The cages were placed in the experimental room 24 h before the test for acclimatization. The animals were fed a standard laboratory diet and tap water ad libitum and kept at 22 ± 1 °C with a 12 h light/dark cycle, light at 7 a.m. All experiments were carried out in accordance with the NIH Guide for the Care and Use of Laboratory animals. All efforts were made to minimize animal suffering and to reduce the number of animals used. Mice were placed inside a stainless steel container, which was set thermostatically at 52.5 ± 0.1 °C in a precision water bath from KW Mechanical Workshop, Siena, Italy. Reaction times (s) were measured with a stopwatch before and 15, 30, 45, and 60 min after administration of analgesic drugs. The endpoint used was the licking of the fore or hind paws. Those mice scoring less than 12 and more than 18 s in the pretest were rejected (30%). An arbitrary cut-off time of 45 s was adopted to avoid injury. No sign of tissue injury was observed up to 45 s. Ten mice per group were tested.
25. The apparatus consisted of a base platform and a rotating rod with a diameter of 3 cm and a non-slippery surface. The rod was placed at a height of 15 cm from the base. The rod, 30 cm in length, was divided into five equal sections by six disks. Thus, up to five mice were tested simultaneously on the apparatus, with a rod-rotating speed of 16 rpm. The integrity of motor coordination was assessed on the basis of the number of falls from the rod in 30 s according to Vaught et al. Those mice scoring less than 3 and more than 6 falls in the pretest were rejected (20%). The performance time was measured before (pretest) and 15, 30, and 45 min after the beginning of the test. Ten mice per group were tested.
26. Vaught J., Pelley K., Costa L.G., Sether P., and Enna S.J. Neuropharmacology 24 (1985) 211
27. Hosohata K., Quock R.M., Hosohata Y., Burkey T.H., Makriyannis A., Consroe P., Roeske W.R., and Yamamura H.I. Life Sci. 61 (1997) PL115